CIM-MEG19 stands as a scientifically validated formulation designed to fortify the immune system against viruses, bacteria, allergens, and more. Central to its efficacy is the standardized extract of Andrographis paniculata (Kalmegh), sourced from carefully selected plant varieties and parts. Andrographis has exhibited capabilities in reducing the duration and severity of upper respiratory infections, including those associated with the common cold and flu, and has demonstrated benefits in alleviating symptoms of conditions such as rheumatoid arthritis. Beyond its immune-boosting properties, Andrographis serves various purposes, acting as an astringent, bacteria-killing agent, painkiller, and fever reducer. It has applications in addressing conditions like sore throat, coughs, bronchitis, and allergies.

Development by CSIR-CIMAP

CIM-MEG19 is the result of years of dedicated research by the Council of Scientific and Industrial Research – Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP), a leading research institute in India since 1959. The institute boasts a team of highly qualified scientists and a state-of-the-art laboratory, emphasizing the integration of traditional Ayurvedic knowledge with modern pharmacological evidence to create globally accepted Phytopharmaceutical products.

Scientific Validation and Efficacy:

The efficacy of CIM-MEG19 is grounded in rigorous scientific validation conducted by CSIR-CIMAP. This includes in-vivo studies attesting to its immunomodulatory, antipyretic, and hepatoprotective properties. Safety evaluations, genotoxicity assessments, and stability studies further contribute to the robust scientific backing of CIM-MEG19. The formulation’s effectiveness is not limited to immunity boosting; it extends to addressing various conditions, from dyspepsia to skin disorders.

Why Choose CIM-MEG19?

CIM-MEG19 distinguishes itself through key attributes:

– Absence of synthetic steroids or hazardous chemicals. – Use of natural herbs from captive cultivation. – Standardized extract derived from specific parts of Andrographis paniculata. – Scientific validation conducted at CSIR-CIMAP. – Pre-clinical proven efficacy in hepatoprotection, antipyretic, analgesic, anti-inflammatory, and immune enhancement. – Defined stability and safety parameters. – Quality assurance through NABL accredited laboratory. – Continuous monitoring for batch-to-batch variation. – Standardized quality formulation.

Dosage:

For adults, the recommended initial dosage is 1-2 tablets 1-3 times a day or as advised by a physician.

Andrographis paniculata for Respiratory Disorders:

The Ayurvedic perspective on pneumonia fever aligns with CIM-MEG19’s potential benefits. Ayurvedic pharmacology attributes respiratory issues, including lung infections, to imbalances in Pitta and Kaphaj-Vata. Scientific literature, including WHO global research on COVID-19, supports the antiviral properties of Andrographis paniculata. While detailed clinical studies are ongoing, there is a recognition of the potential benefits in mitigating the severity of COVID-19 and related disorders.

Conclusion:

CIM-MEG19 emerges as a holistic solution, offering immunity enhancement and addressing a spectrum of health conditions. Rooted in scientific research and developed by CSIR-CIMAP, it stands as a beacon of quality and efficacy in the realm of natural health supplements. Ongoing clinical studies further underscore its potential role in managing COVID-19, aligning with global research findings on the antiviral properties of Andrographis paniculata.